← Azimuth Daily
Capturing data…
Capturing data…
MON, 9 NOV · 75 ITEMS
NEJM, Daily Mail · Science & Medicine
Framing varies: The NEJM reports the trial findings in a clinical, measured tone, while the Daily Mail frames the drug as a 'Holy Grail' cure, emphasizing dramatic patient outcomes and using more sensational language.
This is the headline of a new clinical trial paper published in the New England Journal of Medicine (NEJM) that reports the results of a phase 3 study testing the drug , an that lowers lipoprotein(a) levels, in patients with high baseline lipoprotein(a) — a genetic risk factor for cardiovascular disease. The paper likely presents whether reducing lipoprotein(a) with pelacarsen translates into fewer major adverse cardiovascular events such as heart attacks or strokes.
The claim is highly solid because it is the primary source itself: the actual peer-reviewed paper in NEJM (doi:10.1056/NEJMoa2610159), which is a top-tier medical journal. The reporting is the paper itself, so there is no distance between the claim and the evidence.
This is genuinely new — the paper appears in a current NEJM table of contents, with no indication of being a resurfaced older study.